Rocket Doctor’s marketing partnership with Rick Ware Racing spans the NASCAR Cup Series, NHRA, American Flat Track and World Supercross, with broadcasts reaching national networks including NBC, FOX, USA Network and Amazon Prime. Scale of exposure is not in question. What remains unmeasured, at least in public disclosure so far, is what that exposure converts into.
Yazan Al Homsi, a Vancouver-based investor who holds a disclosed position in Rocket Doctor through Founders Round Capital, has argued the more relevant test is narrower and more measurable: whether the campaign produces physician recruitment, payer or business-development introductions, and patient acquisition in the states where the company is actively expanding, at a cost that justifies the dilution involved.
A more useful comparison than motorsports precedent, on this reading, is Rocket Doctor’s own reimbursement expansion elsewhere in 2026. The company’s California network agreements, including a workers’ compensation and auto medical arrangement announced in August, extend its reach through direct payer and provider relationships rather than consumer brand exposure. If the NASCAR campaign generates physician sign-ups feeding that pipeline, the marketing spend and the reimbursement infrastructure reinforce each other. If it generates awareness without feeding that pipeline, the comparison becomes far less favorable.
Al Homsi holds no board seat or operating role at Rocket Doctor; his commentary reflects his own read as a shareholder. More of his framework for evaluating marketing spend against infrastructure buildout is on his website, and his background is listed on LinkedIn. Scale of broadcast reach, by itself, tells you little about whether that framework’s conditions are being met.